Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. doi: 10.1056/NEJMoa1600176. Yusuf S, HOPE-3 Investigators. Abstract 401-19. Effects of combined lipid ...

Dr Salim Yusuf, president of the World Heart Federation, was careful to note that trials lasting 5 to 6 years, such as HOPE-3, often underestimate the benefits of prevention. Over longer periods of ...

nurse assessing stroke victim 44% drop in stroke for those with intermediate CVD risk receiving candesartan/HCTZ, rosuvastatin (HealthDay News) — For patients with intermediate risk of cardiovascular ...

The analysis included 16,501 participants: 3610 statin users and 12,891 nonusers. HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for ...

Please provide your email address to receive an email when new articles are posted on . Patients who used statins had a reduced risk for HCC, hepatic decompensation and fibrosis progression.

Roughly half of patients who present to the hospital with their first MI would not have been eligible for statin therapy based on two popular risk-assessment tools had they been seen in a cardiology ...

One study explored the use of statins, a class of medications typically used to lower LDL cholesterol levels to reduce the risk of stroke and heart disease. Researchers found that statin use decreased ...

Please provide your email address to receive an email when new articles are posted on . Using visualized coronary calcium scoring independently reduced plaque progression among patients at ...

The US Preventive Services Task Force on Tuesday announced its latest guidelines on the use of statins to prevent a first heart attack or stroke. The recommendations are virtually unchanged from prior ...